|
WO2021046254A1
|
|
Liposomal spherical nucleic acid (sna) constructs for splice modulation
|
|
WO2020219985A1
|
|
Administration of spherical nucleic acids for ophthalmological uses
|
|
WO2020168005A1
|
|
Combined spherical nucleic acid and checkpoint inhibitor for antitumor therapy
|
|
WO2019246409A1
|
|
Il-1 beta targeting spherical nucleic acids
|
|
WO2019169203A1
|
|
Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors
|
|
WO2019168558A1
|
|
Liposomal spherical nucleic acid (sna) constructs for survival of motor neuron (sma) inhibitors
|
|
WO2018201090A1
|
|
Synthesis of spherical nucleic acids using lipophilic moieties
|
|
CA3023451A1
|
|
Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna
|
|
EP3452600A1
|
|
Tlr9-targeted spherical nucleic acids having potent antitumor activity
|
|
US2019225968A1
|
|
Spherical nucleic acid tlr9 agonists
|
|
WO2017184427A1
|
|
Topical administration of therapeutic agents and oligonucleotide formulations
|
|
US2020297867A1
|
|
Surface functionalization of liposomes and liposomal spherical nucleic acids (snas)
|
|
AU2016294594A1
|
|
Spherical nucleic acid (SNA)-mediated delivery of lipid-complexes to cells
|
|
WO2016149323A1
|
|
Immunomodulatory spherical nucleic acids
|
|
WO2016134104A1
|
|
Immuno-regulatory lipid containing spherical nucleic acids
|
|
KR20170104550A
|
|
Nucleic acid nanostructure with core motif
|
|
AU2015328242A1
|
|
Anti-TNF compounds
|
|
KR20170005499A
|
|
Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
|
|
AU2015240567A1
|
|
Self assembling nucleic acid nanostructures
|
|
AU2014292926A1
|
|
Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
|
